Welcome to today’s edition of The Daily Bolus! The incretin landscape is rapidly evolving into the era of the “triple agonist,” with Eli Lilly and Novo Nordisk going head-to-head to push weight loss and A1C reduction to new extremes. Meanwhile, groundbreaking real-world data is showing that these blockbuster therapies are quietly transforming long-term care for the Type 1 diabetes community as well.
Lilly’s Retatrutide Flexes Major Muscle in Phase 3
Eli Lilly announced positive Phase 3 results for retatrutide, its investigational once-weekly triple hormone receptor agonist, in adults with type 2 diabetes. Over a 40-week trial period, patients on the highest 12 mg dose achieved up to a 2.0% reduction in A1C and lost a staggering average of 16.8% of their body weight, or 36.6 pounds.
Why It Matters: For individuals with type 2 diabetes, significant weight loss has notoriously been a difficult hurdle to clear alongside glycemic control. By targeting three separate receptors—GIP, GLP-1, and glucagon—retatrutide pushes the boundaries of metabolic management, offering unprecedented weight loss that impressively did not plateau during the trial.
Novo Nordisk Answers Back with UBT251 Phase 2 Success
Novo Nordisk and its partner, The United Laboratories, shared strong Phase 2 results from China for their own triple agonist candidate, UBT251. In a 24-week study of Chinese patients with type 2 diabetes, the drug achieved up to a 2.16% drop in HbA1c and a 9.8% reduction in body weight, effectively outperforming the 1 mg dose of Novo’s own blockbuster drug, semaglutide.
Why It Matters: This proves the “triple G” approach is the definitive next step beyond today’s highly successful single-agonist GLP-1 treatments like Ozempic. However, with Eli Lilly already wrapping up Phase 3 trials for its rival drug, industry analysts note that Novo Nordisk is currently lagging in the development race. Novo is planning global Phase 2 trials for late 2026, meaning UBT251 could reach the market years after retatrutide, potentially limiting its commercial impact.
GLP-1s Show Real-World Promise for Type 1 Diabetes
A large retrospective analysis from the Cleveland Clinic revealed that using GLP-1 receptor agonists in patients with Type 1 diabetes is associated with lower all-cause mortality and fewer hospital and emergency department visits over a two-year period. Crucially, researchers noted that these therapies did not increase the risk of dangerous diabetes-related complications like diabetic ketoacidosis (DKA) or severe hypoglycemia.
Why It Matters: While GLP-1s are currently only FDA-approved for Type 2 diabetes and obesity, they are increasingly being prescribed off-label for T1D patients who also battle insulin resistance, metabolic syndrome, or obesity. These findings validate that clinical trend, suggesting that adding a GLP-1 to an insulin regimen can safely reduce healthcare utilization and improve long-term outcomes for carefully selected patients with Type 1 diabetes.
The Diabettech Take
The era of the single-receptor incretin agonist is officially on notice. The data we are seeing from “triple G” (GLP-1/GIP/glucagon) agonists—both retatrutide and UBT251—are spectacular, promising massive weight loss alongside exceptional A1C normalization. However, the commercial reality is a race against the clock where Eli Lilly currently holds a clear and commanding head start over Novo Nordisk.
Beyond the corporate heavyweight battle, the Cleveland Clinic data on Type 1 diabetes is perhaps the most paradigm-shifting news of the day. It proves that the future of diabetes care, across both Type 1 and Type 2, is rapidly shifting toward treating the holistic metabolic profile—obesity, insulin resistance, and cardiovascular risk—rather than just chasing glucose numbers.
Discover more from Diabettech - Diabetes and Technology
Subscribe to get the latest posts sent to your email.
Leave a Reply